Time to next treatment by age in the RUBY trial of dostarlimab in endometrial cancer
Автор: VJOncology
Загружено: 2025-07-18
Просмотров: 207
Описание:
Ilana Cass, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses subgroup analyses from the RUBY trial (NCT03981796) evaluating time to first and second subsequent therapy (TFST/TSST) in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin and paclitaxel. Prolonged TFST and TSST were observed with dostarlimab across all age groups, including in the mismatch repair proficient/microsatellite stable population. Safety was consistent across subgroups, supporting the use of this combination as frontline therapy regardless of patient age. This interview took place at 2025 European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
